Get the Stockscreener App
755.02
1.83%
13.57
Pre-market:
749.99
-5.03
-0.67%
Regeneron Pharmaceuticals Inc stock is traded at $755.02, with a volume of 692.59K.
It is up +1.83% in the last 24 hours and down -2.74% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$741.45
Open:
$732.92
24h Volume:
692.59K
Relative Volume:
0.71
Market Cap:
$79.35B
Revenue:
$14.34B
Net Income/Loss:
$4.50B
P/E Ratio:
18.16
EPS:
41.5659
Net Cash Flow:
$3.88B
1W Performance:
-1.00%
1M Performance:
-2.74%
6M Performance:
+35.10%
1Y Performance:
+12.19%
1-Day Range:
$731.51
$763.56
1-Week Range:
$731.51
$776.25
52-Week Range:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
755.02 | 77.93B | 14.34B | 4.50B | 3.88B | 41.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.01 | 119.22B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ARGX
Argen X Se Adr
|
835.68 | 52.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.11 | 44.66B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
345.00 | 37.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Feb 02, 2026 BMO Maintains Outperform on REGN (Regeneron Pharmaceuticals, Inc.) - Meyka
Does Modest 2025 Results and New EYLEA HD Data Shift the Bull Case for Regeneron (REGN)? - simplywall.st
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: A Promising 15% Upside as Analysts Rally Behind Biotech Giant - DirectorsTalk Interviews
Regeneron Stock Slips Premarket Even After Wall Street Lifts Targets On Strong Q4 — What’s Weighing On The Stock? - Stocktwits
Where Regeneron Pharmaceuticals Stands With Analysts - Benzinga
JP Morgan Raises Price Target for REGN to $950 | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $950.00 at JPMorgan Chase & Co. - MarketBeat
Regeneron Pharmaceuticals (REGN) Gets Analyst Boost with Revised Price Target | REGN Stock News - GuruFocus
Oppenheimer Reaffirms Outperform Rating for Regeneron Pharmaceuticals (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $769.00 at Morgan Stanley - MarketBeat
Analyst Matthew Harrison Maintains Equal-Weight Rating for REGN | REGN Stock News - GuruFocus
Wells Fargo Raises Price Target for Regeneron Pharmaceuticals (R - GuruFocus
REGN: Cantor Fitzgerald Raises Price Target to $800, Maintains O - GuruFocus
Cantor Fitzgerald Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $800.00 - MarketBeat
Truist Financial Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Truist Securities Maintains Buy Rating on REGN, Lowers Price Target | REGN Stock News - GuruFocus
Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $925 From $916, Maintains Outperform Rating - marketscreener.com
Regeneron (REGN) Boosts Dividend by 6.8%, Expects Strong Growth - GuruFocus
Oppenheimer Raises Price Target on Regeneron Pharmaceuticals to $865 From $750, Keeps Outperform Rating - marketscreener.com
Regeneron to present new EYLEA HD data at Angiogenesis meeting - Investing.com
Regeneron (REGN) Highlights Advances in Ophthalmology with EYLEA HD - GuruFocus
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases - The Manila Times
Eye drug EYLEA HD offers fewer eye injections in fresh trial data - Stock Titan
This Top Non-Tech AI Trade for 2026 Pays a Huge 11.6% Dividend - Investing.com
AE Wealth Management LLC Buys 1,371 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron stock slips premarket even after Wall Street lifts targets on strong Q4 — what’s weighing on the stock? - MSN
Great Lakes Advisors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA Action Alert: Sanofi/Regeneron, Merck, REGENXBIO and More - BioSpace
Regeneron Pipeline Progress And Valuation Gap Put Future Growth In Focus - Yahoo Finance
Regeneron Q4 Growth Highlights Expanding Pipeline And Upcoming FDA Decisions - simplywall.st
National Pension Service Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Aug Catalysts: Is Regeneron Pharmaceuticals Inc part of any ETFJuly 2025 Technicals & Consistent Growth Equity Picks - baoquankhu1.vn
Regeneron (REGN) Draws Higher Target From TD Cowen - Finviz
Regeneron Pharmaceuticals, Inc. (REGN) Posts Q4 Earnings Beat, EPS Shines - Finviz
How Regeneron Pharmaceuticals Inc. (REGN) Affects Rotational Strategy Timing - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Stryker (SYK), Regeneron (REGN) and NewAmsterdam Pharma Company (NAMS) - The Globe and Mail
Regeneron: Expect Double-Digit Growth In 2026 - Seeking Alpha
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by TD Waterhouse Canada Inc. - MarketBeat
Wall Street Zen Downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold - MarketBeat
Regeneron Pharmaceuticals (REGN) Margin Slippage Tests Bullish Earnings Growth Narrative - simplywall.st
10 Most Profitable Healthcare Stocks to Buy - Insider Monkey
Regeneron’s Earnings Call: Growth Engines and Rising Costs - TipRanks
Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025 - The Globe and Mail
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Raises Dividend to $0.94 Per Share - MarketBeat
Regeneron (REGN) Reports Strong Q4 2025 Revenue Growth - GuruFocus
Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Highl - GuruFocus
Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Regeneron Pharmaceuticals: Robust 4Q25 Beat, Underappreciated Pipeline Upside, and 2026 Catalysts Support Buy Rating and $870 Target - TipRanks
Key facts: Regeneron gains FDA approval; Q4 revenue rises 3%; trials for weight-loss drug start - TradingView
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):